1
|
Quéré B, Lemelle I, Lohse A, Pillet P, Molimard J, Richer O, Sordet C, Despert V, Rossi-Semerano L, Borocco C, Kone-Paut I, Gervais E, Guellec D, Devauchelle-Pensec V. Juvenile Idiopathic Arthritis and COVID-19 Pandemic: Good Compliance With Treatment, Reluctance to Return to School. Front Med (Lausanne) 2021; 8:743815. [PMID: 34869435 PMCID: PMC8632709 DOI: 10.3389/fmed.2021.743815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2021] [Accepted: 10/21/2021] [Indexed: 11/23/2022] Open
Abstract
Objective: The SARS-CoV-2 pandemic has induced an exceptional sanitary crisis, potentially having an impact on treatment continuation, for juvenile idiopathic arthritis (JIA) patients receiving immunosuppressive therapies. After national lockdowns, many patients were also concerned about their safety at school. We evaluated the impact of the pandemic on the optimal continuation of treatment and on the return to school in JIA patients. Methods: JIA patients under 18 years of age, usually treated with disease-modifying anti-rheumatic drugs (DMARDs) were prospectively included during their outpatient visit and completed a standardized questionnaire. The primary outcome was DMARD treatment modification in relation to the context of the pandemic but we also evaluated the pandemic's impact on the schooling. Results: One hundred and seventy three patients from 8 different expert centers were included between May and August 2020. Their mean age was 11.6 years (± 4.1 years), and most of them 31.2% (54/173) had a rheumatoid factor-negative polyarticular JIA. Fifty percent (86/172) were treated with methotrexate, and 72.5% (124/171) were treated with bDMARDs. DMARD treatment modification in relation to the pandemic was observed in 4.0% (7/173) of participants. 49.1% (81/165) of the patients did not return to school due to a personal/parental decision in 69.9% (55/81) of cases. Two patients were diagnosed positive for SARS-CoV-2 infection. Conclusion: This study suggests that JIA patients treated with DMARDs continued their treatment during the pandemic and were rarely affected by symptomatic COVID-19. In contrast, parents' reluctance was a major obstacle for returning to school. Therefore, more solidified school reopening strategies should be developed.
Collapse
Affiliation(s)
- Baptiste Quéré
- Department of Rheumatology, Cavale Blanche Hospital, Brest University, Brest, France
| | - Irene Lemelle
- Paediatric Onco-Haematology, Brabois Hospital, University Hospital of Nancy, Vandoeuvre-Lès-Nancy, France
| | - Anne Lohse
- Department of Rheumatology, Nord Franche-Comté Hospital, Belfort, France
| | - Pascal Pillet
- Paediatrics, Rheumatology and Paediatric Internal Medicine, Children's Hospital, Bordeaux, France
| | - Julie Molimard
- Paediatrics, Rheumatology and Paediatric Internal Medicine, Children's Hospital, Bordeaux, France
| | - Olivier Richer
- Paediatrics, Rheumatology and Paediatric Internal Medicine, Children's Hospital, Bordeaux, France
| | - Christelle Sordet
- Department of Rheumatology, University Hospital of Strasbourg, Strasbourg, France
| | | | - Linda Rossi-Semerano
- Department of Paediatric Rheumatology, National Reference Centre for Auto-inflammatory Diseases and Amyloidosis of Inflammatory Origin (CEREMAIA), Assistance Publique-Hôpitaux de Paris (AP-HP), University of Paris Sud Sacaly, Le Kremlin-Bicêtre, France
| | - Charlotte Borocco
- Department of Paediatric Rheumatology, National Reference Centre for Auto-inflammatory Diseases and Amyloidosis of Inflammatory Origin (CEREMAIA), Assistance Publique-Hôpitaux de Paris (AP-HP), University of Paris Sud Sacaly, Le Kremlin-Bicêtre, France
| | - Isabelle Kone-Paut
- Department of Paediatric Rheumatology, National Reference Centre for Auto-inflammatory Diseases and Amyloidosis of Inflammatory Origin (CEREMAIA), Assistance Publique-Hôpitaux de Paris (AP-HP), University of Paris Sud Sacaly, Le Kremlin-Bicêtre, France
| | - Elisabeth Gervais
- Department of Rheumatology, University Hospital of Poitiers, Poitiers, France
| | - Dewi Guellec
- Department of Rheumatology, Cavale Blanche Hospital, Brest University, Brest, France
| | | |
Collapse
|
2
|
Richette P, Allez M, Descamps V, Perray L, Pilet S, Latourte A, Maravic M. Impact of COVID-19 on initiation of biologic therapy prescriptions for chronic inflammatory diseases. Joint Bone Spine 2021; 89:105253. [PMID: 34314887 PMCID: PMC8305295 DOI: 10.1016/j.jbspin.2021.105253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2021] [Accepted: 07/13/2021] [Indexed: 12/03/2022]
Affiliation(s)
- Pascal Richette
- Rheumatology department, Lariboisière Hospital, AP-HP, 2, rue Ambroise Paré, 75010 Paris, France; Inserm U1132, Paris University, Paris, France.
| | - Matthieu Allez
- Gastro Enterology department, St-Louis Hospital, AP-HP, Paris, France
| | | | | | | | - Augustin Latourte
- Rheumatology department, Lariboisière Hospital, AP-HP, 2, rue Ambroise Paré, 75010 Paris, France; Inserm U1132, Paris University, Paris, France
| | | |
Collapse
|